Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06144944CT.gov Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05020860CT.gov Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer | — | Recruiting | — | — | — |
NCT05177796CT.gov Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer | — | Withdrawn | — | — | — |
NCT04448886CT.gov Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC | — | Active Not Recruiting | — | — | — |
NCT04230109CT.gov Sacituzumab Govitecan In TNBC | — | Recruiting | — | — | — |
NCT04398914CT.gov Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04243616CT.gov Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03595592CT.gov Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02860000CT.gov Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer | — | Completed | — | — | — |
NCT03497702CT.gov Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer | — | Unknown | — | — | — |
Show 5 more trialsShow fewer
NCT02957968CT.gov Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca | — | Active Not Recruiting | — | — | — |
NCT02954874CT.gov Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT00635050CT.gov Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin | — | Completed | — | — | — |
NCT00486668CT.gov A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer | — | Unknown | — | — | — |
NCT00429182CT.gov Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Invasive Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | P3 | BB · 65 |
| Tamoxifen | University of California, San Francisco | P4 | BBB |
| Letrozole | Emory University | P4 | BBB |
| Anastrozole | Jonsson Comprehensive Cancer Center | P4 | BBB |
| Exemestane | University of California, San Francisco | P4 | BBB |
| Trastuzumab | Massachusetts General Hospital | P3 | BB |
| Fulvestrant | Massachusetts General Hospital | P2 | BB |
| Carboplatin | Baylor Breast Care Center | P3 | BB |
| Pertuzumab | Baylor Breast Care Center | P3 | BB |
+42 more in the Invasive Breast Carcinoma cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cyclophosphamide in Invasive Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-invasive-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →